Trial · NCT04399538
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Treatment | STARTED | Placebo | 15 | |
| Double-Blind Treatment | STARTED | PF-06865571 25 mg Twice Daily (BID) + PF-05221304 10 mg BID | 15 | |
| Double-Blind Treatment | STARTED | PF-06865571 100 mg BID + PF-05221304 10 mg BID | 13 | |
| Double-Blind Treatment | STARTED | PF-06865571 300 mg Once Daily (QD) + PF-05221304 20 mg QD | 18 | |
| Double-Blind Treatment | STARTED | PF-06865571 300 mg BID + PF-05221304 10 mg BID | 14 | |
| Double-Blind Treatment | COMPLETED | Placebo | 15 | |
| Double-Blind Treatment | COMPLETED | PF-06865571 25 mg Twice Daily (BID) + PF-05221304 10 mg BID | 15 | |
| Double-Blind Treatment | COMPLETED | PF-06865571 100 mg BID + PF-05221304 10 mg BID | 13 | |
| Double-Blind Treatment | COMPLETED | PF-06865571 300 mg Once Daily (QD) + PF-05221304 20 mg QD | 17 | |
| Double-Blind Treatment | COMPLETED | PF-06865571 300 mg BID + PF-05221304 10 mg BID | 12 | |
| Double-Blind Treatment | NOT COMPLETED | Placebo | 0 | |
| Double-Blind Treatment | NOT COMPLETED | PF-06865571 25 mg Twice Daily (BID) + PF-05221304 10 mg BID | 0 | |
| Double-Blind Treatment | NOT COMPLETED | PF-06865571 100 mg BID + PF-05221304 10 mg BID | 0 | |
| Double-Blind Treatment | NOT COMPLETED | PF-06865571 300 mg Once Daily (QD) + PF-05221304 20 mg QD | 1 | |
| Double-Blind Treatment | NOT COMPLETED | PF-06865571 300 mg BID + PF-05221304 10 mg BID | 2 | |
| Follow-Up | STARTED | Placebo | 15 | |
| Follow-Up | STARTED | PF-06865571 25 mg Twice Daily (BID) + PF-05221304 10 mg BID | 15 | |
| Follow-Up | STARTED | PF-06865571 100 mg BID + PF-05221304 10 mg BID | 13 | |
| Follow-Up | STARTED | PF-06865571 300 mg Once Daily (QD) + PF-05221304 20 mg QD | 17 | |
| Follow-Up | STARTED | PF-06865571 300 mg BID + PF-05221304 10 mg BID | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04399538/flow